NCT07380867Enrolling by invitation
Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.
Localization of Preoperative Endoscopic Tattooing Using Indocyanine Green(ICG)-Hyaluronic Acid Mixture (Luminomark) for Colorectal Cancer Surgery
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
Early-stage lesions are difficult to identify intraoperatively during colorectal cancer surgery. Therefore, preoperative lesion marking using a colonoscopic approach is crucial to confirm the location and extent of resection during surgery. Preoperative lesion location can help determine the optimal extent of resection, thereby increasing the accuracy of colorectal surgery. This is particularly true for cases requiring surgery after early-stage colorectal cancer or endoscopic tumor resection. Therefore, preoperative marking with indocyanine green (IDG) allows for laparoscopic identification of the lesion. This is crucial because it allows for precise lesion location, thereby enhancing surgical accuracy and preventing the need for unnecessary additional resections.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 21 Dec 2025
- Start date
- 22 Dec 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Seoul St. Mary's Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT07380867
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 22 Dec 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- High risk of intestinal obstruction or perforation
- Patients deemed inappropriate by the investigator (high-risk patients, such as patients with lung or heart disease, risk factors for bleeding, hepatitis virus infection, or other cancers)
- Patients with a history of hypersensitivity to the luminomarker drug or its components
- Patients who have experienced skin hypersensitivity to the dye
Lab values
- Severe hepatic or renal dysfunction (Child-Pugh Class C, eGFR \<39 mL/min/1.73 m2)
Other
- Patients diagnosed with distant metastases (M1)
- Pregnant or lactating women
- Patients who do not wish to participate in the study
Who the study is looking for
- Adult patients aged 19-80 years
- Clinical T1-2, N0, without distant metastasis on imaging
- If surgical treatment is required after ESD (endoscopic mucosal resection)\*
- If endoscopic lesion marking is required as determined by the attending physician
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul St. Mary's Hospital, The Catholic University of Korea Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.